logo
ENTITY
Suzhou Zelgen Biopharmaceutica

Suzhou Zelgen Biopharmaceutica (688266 CH)

20
Analysis
Health Care • China
Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches, develops, manufactures, and sells new medications. The Company provides small molecule targeted drugs, recombinant protein drugs, and other treatments of cancer, blood diseases, hepatobiliary diseases, and more. Suzhou Zelgen Biopharmaceuticals markets its drugs domestically.
more
Exchange Announcement • 11 Jan 2021 17:31

Announcement On Voluntary Disclosure Of Clinical Trial Progress Of New Type 1 Drug Jacketinib Hydrochloride Tablets (关于自愿披露1类新药盐酸杰克替尼片临床试验进展的公告)

Exchange Announcement • 30 Dec 2020 17:39

Announcement On Voluntary Disclosure Of Receipt Of On-Site Inspection Notice For Drug Registration Of Donafenib Tosylate Tablets (关于自愿披露收到甲苯磺酸多纳非尼片药品注册现场核查通知的公告)

Exchange Announcement • 22 Dec 2020 16:19

Announcement Of Resolutions Of The 15th Meeting Of The First Board Of Supervisors (第一届监事会第十五次会议决议公告)

Exchange Announcement • 16 Dec 2020 17:31

Announcement On Voluntary Disclosure Of The Company’S Research Products Obtained Fda Orphan Drug Qualification (关于自愿披露公司在研产品获得Fda孤儿药资格认定的公告)

Exchange Announcement • 16 Dec 2020 17:14

China International Capital Corporation'S Verification Opinion On The Voluntary Disclosure Of Donafinil-Related Information By Suzhou Zejing Biopharmaceutical Co., Ltd. (中国国际金融股份有限公司关于苏州泽璟生物制药股份有限公司自愿披露多纳非尼相关信息的核查意见)

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3

x